NovoSeven RT (generic name: recombinant coagulation Factor VII) is an injectable medication used to control bleeding episodes and prevent bleeding during surgeries and procedures in adults and children with specific bleeding disorders. These include hemophilia A or B with inhibitors, congenital Factor VII deficiency, and Glanzmann’s thrombasthenia. It may also be used during the treatment of bleeding and to prevent bleeding in adults with acquired hemophilia who are undergoing surgery and procedures.
Recombinant coagulation factor VIIa (rFVIIa) is a man-made protein designed to mimic the natural clotting factor VIIa in the body, used to help blood clot. It’s particularly important for treating bleeding episodes in individuals with hemophilia who have developed antibodies against traditional clotting factors. rFVIIa is also used in other conditions where traditional hemostatic measures are insufficient.
Dosage
NovoSeven RT is administered by injection. Patients who have been trained may be able to self-administer. Otherwise, it should be done only in a clinical environment under the supervision of a healthcare provider.
This text is for informational purposes only. Please consult a doctor or pharmacist before using any medication.Â
NovoSeven RT may cause serious blood clots that form in veins and arteries. Doctors should have discussed the risks and explained the signs and symptoms of blood clots. Some of these include pain, swelling, warmth, redness, or a lump in the legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function. Healthcare providers usually monitor patients for signs of blood clots during treatment.
Doctors prescribe this medication because they assess the benefits of such treatment outweigh any likely unwanted effects.
Some of the side effects that have been reported include fever, headache, dizziness, nausea, or vomiting may occur.Â
Not all side effects are listed here. If these or other unlisted symptoms persist or worsen, consult a healthcare provider or pharmacist.
Patients who have blood-clotting disorders such as hemophilia types A and B may require special blood-clotting facilitation if they have uncontrolled bleeding episodes after injury or are having to underego surgical procedures. Factor VIIa is a man-made protein that mimics the naturally occurring clotting activator in the body. It is used to stop bleeding in patients by helping the blood to clot.